The Oswestry Metabolic BONE Cohort

Launched by ROBERT JONES AND AGNES HUNT ORTHOPAEDIC AND DISTRICT NHS TRUST · Jun 2, 2025

Keywords

ClinConnect Summary

The Oswestry Metabolic BONE Cohort is a clinical trial aimed at better understanding osteoporosis, a condition that weakens bones and increases the risk of fractures, especially in older adults. The study will look at various factors that affect bone health, including not only bone density but also other health conditions like obesity, diabetes, and muscle strength. By gathering data on these factors, researchers hope to improve how we predict fracture risks and develop better treatment strategies for patients.

To be eligible for the trial, participants must be postmenopausal women or men over 50 years old who have experienced a fragility fracture in the past two years. This includes fractures in areas like the spine, hip, or wrist. Participants should have a bone density measurement taken between 2025 and 2035 and should not currently be on anti-osteoporosis medication. While the trial is not yet recruiting, it represents an important step in advancing our understanding of osteoporosis and how to prevent fractures in those at risk. If you join the study, you can expect to contribute to valuable research that may benefit many others facing similar health challenges.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: • Postmenopausal women and men \> 50 years old
• • A fragility fracture sustained during two years prior to the baseline DXA including spine, hip, wrist, humerus, pelvis, elbow, rib, sternum, clavicle, scapula, distal femur, tibia, fibula, and foot
• • A DXA measurement at the lumbar spine and hip between 2025-2035
• • Non-osteoporotic BMD (T-score \>-2.5) and
• • Anti-osteoporosis therapy not recommended following the DXA scan
• Exclusion Criteria:
• • Traumatic fracture
• • Patients who lack capacity.